Modulating commensal bacteria to intervene in cancer immunotherapy

References

[1] Jiang Y, Jia D, Sun Y, Ding N, Wang L. Microbiota: a key factor affecting and regulating the efficacy of immunotherapy. Clin Transl Med. 2023;13:e1508.

[2] Jia D, Wang Q, Qi Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187:1651-1665. e1621

[3] Bender MJ, McPherson AC, Phelps CM, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023;186:1846-1862. e1826

[4] Jiang SS, Xie YL, Xiao XY, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31:781-797. e789

[5] Fong W, Li Q, Ji F, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023;72:2272-2285.

[6] Xue C, Li G, Zheng Q, et al. Tryptophan metabolism in health and disease. Cell Metab. 2023;35:1304-1326.

[7] Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23:716-724.

[8] Serger E, Luengo-Gutierrez L, Chadwick JS, et al. The gut metabolite indole-3 propionate promotes nerve regeneration and repair. Nature. 2022;607:585-592.

[9] Wang YC, Koay YC, Pan C, et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction. Circ Res. 2024;134:371-389.

[10] Cao B, Zhao RY, Li HH, et al. Oral administration of asparagine and 3-indolepropionic acid prolongs survival time of rats with traumatic colon injury. Mil Med Res. 2022;9:37.

[11] Zhao X, Shan Q, Xue HH. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2022;22:147-157.

[12] Yu G, Wang F, You M, et al. TCF-1 deficiency influences the composition of intestinal microbiota and enhances susceptibility to colonic inflammation. Protein Cell. 2020;11:380-386.

[13] Paik D, Yao L, Zhang Y, et al. Human gut bacteria produce Τ(Η)17-modulating bile acid metabolites. Nature. 2022;603:907-912.

[14] Needham BD, Funabashi M, Adame MD, et al. A gut-derived metabolite alters brain activity and anxiety behaviour in mice. Nature. 2022;602:647-653.

[15] Gao Y, Xu P, Sun D, et al. Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade. Cancer Res. 2023;83:3710-3725.

[16] Lo BC, Kryczek I, Yu J, et al. Microbiota-dependent activation of CD4(+) T cells induces CTLA-4 blockade-associated colitis via Fcγ receptors. Science. 2024;383:62-70.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.